SLFN12 and cancer: Interestingly, existing literature suggests that hypermethylation-mediated silencing of SLFN11 and SLFN12 disrupts DNA damage recognition, impairs apoptosis, and promotes chemoresistance across multiple cancers, allowing malignant cells to persist despite therapeutic intervention.